Omega-3 Epoxyeicosanoid Analog Discovery Platform
exploratoryplatform · high · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop metabolically robust synthetic analogs of omega-3 fatty acid-derived epoxyeicosanoids for cardiovascular, inflammatory, and mitochondrial disease applications.
Small-molecule design based on 17,18-EEQ and related CYP-derived omega-3 epoxyeicosanoid biology, including development of robust 17,18-EEQ analogs such as OMT-28 and C21.
Pipeline and publication corpus support continued development of omega-3 epoxyeicosanoid analog programs, led by OMT-28.
Publications report anti-inflammatory, cardioprotective, antiarrhythmic, mitochondrial, pulmonary hypertension, and ophthalmology-relevant effects of omega-3 epoxyeicosanoids and stable analogs.
OMT-28 for Acute Respiratory Distress Syndrome / Lung Injury
preclinicalresearch program · high · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate whether OMT-28 protects against inflammatory lung injury and preserves epithelial barrier integrity through mitochondrial and SIRT3-related effects.
Murine LPS-induced acute respiratory distress syndrome model plus in vitro studies in human bronchial epithelial BEAS-2B cells and human alveolar epithelial A549 cells.
Preclinical OMT-28 lung injury study published in 2025.
OMT-28 improved post-injury survival, reduced inflammatory cell infiltration, vascular permeability, inflammatory cytokines, NF-kB phosphorylation, and mitochondrial dysfunction; SIRT3 silencing abolished protective effects in epithelial cell models.
OMT-28 for Primary Mitochondrial Disease
phase 2drug program · high · Thu Sep 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate safety, tolerability, biomarker effects, and clinical symptom effects of OMT-28 in patients with Primary Mitochondrial Disease, including GDF-15 and other markers of mitochondrial dysfunction and inflammation, fatigue, and exercise intolerance.
Open-label Phase 2a clinical trial of once-daily OMT-28 with comparison of outcomes after 3 and 6 months of treatment against a preceding 3-month standard-care period.
Patient enrollment completed for the Phase 2a PMD-OPTION study.
OMT-28 Cardioprotection and Endotoxemia
preclinicalresearch program · high · Mon Jan 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate whether OMT-28 mimics omega-3 epoxyeicosanoid cardioprotective and anti-inflammatory effects in cardiac injury and endotoxemia models.
Cultured cardiomyocyte hypoxia/reoxygenation and LPS models plus isolated perfused mouse-heart ischemia/reperfusion experiments.
Cardioprotective properties of OMT-28 publication listed in 2024.
OMT-28 preserved cardiomyocyte viability and mitochondrial function, reduced mitochondrial reactive oxygen species, reduced LPS-induced TNF-alpha and NF-kB activity, and improved post-ischemia/reperfusion myocardial functional recovery in mouse hearts.
Omega-3 Epoxyeicosanoids for Pulmonary Hypertension
preclinicalresearch program · medium · Sat Jan 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Investigate whether omega-3 epoxyeicosanoids can counteract development of pulmonary hypertension.
Preclinical research on omega-3 epoxyeicosanoid effects in pulmonary hypertension models.
Pulmonary hypertension publication listed in 2022.
OMT-28 for Persistent Atrial Fibrillation
phase 2drug program · high · Wed Jan 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate OMT-28 for maintenance of sinus rhythm in patients with persistent atrial fibrillation.
Randomized, double-blind, dose-finding, placebo-controlled, parallel-group, multicenter Phase II study comparing three once-daily OMT-28 doses versus placebo, with efficacy, safety, and population pharmacokinetic assessments.
Phase II study registered and rationale/design publication listed.
OMT-28 First-in-Human Safety and Pharmacokinetics
phase 1drug program · high · Wed Mar 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Assess safety, tolerability, pharmacokinetics, and exploratory pharmacodynamics of OMT-28 to support further clinical development, including atrial fibrillation dosing.
First-in-human study of single and multiple oral ascending doses of OMT-28 in healthy male subjects, including food and gender-effect assessments.
Phase 1 clinical trial initiated and registered.
17,18-EEQ / C21 for Wet Age-Related Macular Degeneration
preclinicalresearch program · medium · Sun Jan 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate 17,18-EEQ and the stable synthetic analog C21 for reducing choroidal neovascularization in wet age-related macular degeneration through an immunomodulatory mechanism.
Preclinical ophthalmology research assessing 17,18-EEQ and C21 effects on choroidal neovascularization.
Wet AMD-related 17,18-EEQ and C21 publications listed for 2013 and 2017.
Supplied publication titles state that 17,18-EEQ and C21 reduce choroidal neovascularization via an immunomodulatory mechanism.
